



ASX ANNOUNCEMENT

SIGNIFICANT ADVANCE IN DEVELOPMENT OF ACTINOGEN MEDICAL'S ALZHEIMERS DRUG XANAMEM™

- Xanamem™ human research data accepted for publication in major medical journal
- Xanamem™ specifically designed to inhibit excess cortisol production in the brain
- Excess cortisol in the brain associated with Alzheimer's disease
- Xanamem™ being trialled in Alzheimer's disease to confirm earlier treatment success

Sydney, December 19, 2016: In a significant advance in the development of Xanamem™, **Actinogen Medical Limited (ASX:ACW)** is pleased to announce that their human research data on Xanamem™ has been accepted for publication in the prestigious peer-reviewed medical journal – the British Journal of Pharmacology. The paper: *Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™)* will be available online early in the new year.

Publication of these results endorses the integrity of the research on Xanamem™ and affirms the significant potential of the drug as an effective treatment for Alzheimer's disease.

Xanamem™ has been specifically designed to block excess production of cortisol, the stress hormone, in the areas of the brain most affected in Alzheimer's disease. Raised cortisol has been strongly associated with Alzheimer's disease and lowering cortisol in the brain is an important new target for treating Alzheimer's disease.

Actinogen Medical is currently conducting XanADu, the largest global Alzheimer's disease clinical trial ever run by an Australian biotech company, to confirm earlier results that demonstrated that Xanamem™ could successfully treat Alzheimer's disease, in an animal model of the disease. Recruitment and treatment of patients is expected to start in early 2107.

Alzheimer's disease has become one of the biggest public health challenges for modern society. It is the biggest killer in the UK and second only to heart disease in Australia. Current medicines to treat Alzheimer's disease provide only marginal benefit and new therapies are desperately needed to help manage this devastating disease.

ENDS

Actinogen Medical

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

About Actinogen Medical

Actinogen Medical (ASX: ACW) is an ASX-listed biotech company focused on innovative approaches to treating cognitive decline that occurs in chronic neurodegenerative and metabolic diseases. Xanamem™, Actinogen Medical's lead candidate drug, blocks excess production of the stress hormone cortisol in the brain. There is

ACTINOGEN MEDICAL LIMITED TRADING AS ACTINOGEN MEDICAL ACN 086 778 476 ASX | ACW

Level 9, Suite 1, 68 Pitt Street, Sydney NSW 2000 AUSTRALIA

TELEPHONE +61 2 8964 7401

WEB www.actinogen.com.au

growing evidence that chronic stress and excess cortisol leads to changes in the brain affecting memory, and to the development of amyloid plaques and neural death – all hallmarks of Alzheimer’s disease. In 2016, the Company initiated XanADu, a Phase II efficacy and safety trial of Xanamem™ in mild Alzheimer’s disease.

About Xanamem™

Xanamem™ is being developed as a promising new therapy for Alzheimer’s disease, a condition with a multibillion dollar market potential. In the US alone, the cost of managing Alzheimer’s disease in 2013 was estimated to be US\$250bn, and is set to increase to US\$1 trillion by 2050, outstripping the treatment costs of all other diseases. Alzheimer’s disease is now the second leading cause of death in Australia, behind ischaemic heart disease. Xanamem™’s novel mechanism of action sets it apart from other Alzheimer’s treatments. It works by blocking the excess production of cortisol - the stress hormone - in the hippocampus and frontal cortex, the areas of the brain most affected by Alzheimer’s disease.

Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.